Skip to content

US · DFTX · BIOTECHNOLOGY

Definium Therapeutics, Inc. (DFTX) intrinsic value and stock valuation

$28.34as of 2026-11-21 · Mkt cap 4.84B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Definium Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values DFTX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from DFTX’s statements →

Definium Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology New York, NY 10007 definiumtx.com

How the business is doing

Fiscal 2015–2025, USD

Revenue
$0.00
20152025
Net income
-$-183.79M
20152025
Free cash flow
-$-131.56M
20152025
Total equity
$332.3M+34.4% 5y CAGRd
20152025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2015–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-166.31M-$-103.92M-$-93.87M-$-66.33M-$-93.85M
Net income-$-183.79M-$-108.68M-$-95.73M-$-56.8M-$-93.04M
EPSd-$-2.06M-$-154.24K-$-2.44M-$-1.84M-$-3.4M
Operating cash flow-$-131.56M-$-79.13M-$-64.36M-$-50.14M-$-45.82M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-131.56M-$-79.13M-$-64.36M-$-50.14M-$-45.82M
Total assets$440.1M$302.2M$124.5M$170M$164M
Total debt$0.00$21.9M$14.1M$70K$0.00
Net debt-$-257.84M-$-251.89M-$-85.58M-$-142.07M-$-133.54M
Total equity$332.3M$241.5M$78.1M$150.9M$151.7M
Cash and short-term investments$411.6M$273.7M$99.7M$142.1M$133.5M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$530K$3.16M$0.00$0.00
Gross profit$0.00-$-530K-$-3.16M$0.00$0.00
Research and development expenses$117.7M$65.3M$49M$36.2M$34.8M
Selling, general and administrative expenses$48.6M$38.6M$41.7M$30.2M$59.1M
Other expenses$0.00-$-530K$0.00$0.00$0.00
Operating expenses$166.3M$103.4M$90.7M$66.3M$93.9M
Cost and expenses$166.3M$103.9M$93.9M$66.3M$93.9M
Interest income$11M$11.6M$5.58M$1.5M$0.00
Interest expense$5.48M$2.28M$920K$1.5M$360K
Depreciation and amortization$0.00$530K$3.16M$3.18M$2.62M
Ebitda-$-178.31M-$-105.87M-$-92.57M-$-52.12M-$-91.22M
Operating income-$-166.31M-$-103.92M-$-93.87M-$-66.33M-$-93.85M
Total other income/expenses, net-$-17.48M-$-4.76M-$-1.87M$9.54M-$-340K
Income before tax-$-183.79M-$-108.68M-$-95.73M-$-56.8M-$-94.19M
Income tax expense$0.00$0.00$0.00$0.00-$-1.16M
Net income-$-183.79M-$-108.68M-$-95.73M-$-56.8M-$-93.04M
Weighted average shares outstanding$89.3M$70.5M$39.2M$30.9M$27.4M
Weighted average diluted shares outstanding$89.3M$704.6M$39.2M$30.9M$27.4M
Balance sheet
20252024202320222021
Cash and short-term investments$411.6M$273.7M$99.7M$142.1M$133.5M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$419.3M$281.6M$103.9M$146.1M$137.2M
Property, plant and equipment, net$0.00$0.00$0.00$0.00$0.00
Goodwill and intangible assets$19.9M$19.9M$20.5M$23.6M$26.8M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$20.8M$20.5M$20.7M$23.9M$26.8M
Total assets$440.1M$302.2M$124.5M$170M$164M
Accounts payable$5.35M$2.01M$4.14M$2.11M$4.18M
Short-term debt$0.00$0.00$0.00$70K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$66.7M$38.9M$32.3M$17.9M$10.4M
Long-term debt$0.00$21.9M$14.1M$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$41.1M$21.9M$14.2M$1.18M$1.93M
Capital lease obligations$0.00$0.00$0.00$70K$0.00
Total liabilities$107.8M$60.7M$46.4M$19.1M$12.3M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-582.67M-$-398.88M-$-290.2M-$-194.47M-$-137.67M
Accumulated other comprehensive income (loss)$1.08M$820K$340K$630K$1.05M
Total equity$332.3M$241.5M$78.1M$150.9M$151.7M
Total investments$153.8M$0.00$0.00$0.00$0.00
Total debt$0.00$21.9M$14.1M$70K$0.00
Net debt-$-257.84M-$-251.89M-$-85.58M-$-142.07M-$-133.54M
Cash flow statement
20252024202320222021
Net income-$-183.79M-$-108.68M-$-95.73M-$-56.8M-$-93.04M
Depreciation and amortization$0.00$530K$3.16M$3.18M$2.62M
Stock-based compensation$20.1M$16.9M$15.5M$13.7M$42.7M
Change in working capital$9.44M-$-3.34M$6.28M-$-3.78M$1.88M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$3.34M-$-2.13M$2.02M-$-2.06M$1.28M
Net cash provided by operating activities-$-131.56M-$-79.13M-$-64.36M-$-50.14M-$-45.82M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00-$-300K
Net cash used for investing activities-$-151.61M$0.00$0.00$0.00-$-300K
Common stock issued$259.9M$250M$7.53M$42.3M$81.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$267.3M$253.2M$21.9M$59.1M$98.8M
Net change in cash-$-15.9M$174M-$-42.44M$8.6M$53.5M
Cash at end of period$257.8M$273.7M$99.7M$142.1M$133.5M
Operating cash flow-$-131.56M-$-79.13M-$-64.36M-$-50.14M-$-45.82M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-131.56M-$-79.13M-$-64.36M-$-50.14M-$-45.82M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Definium Therapeutics, Inc.

        Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.

        CEO
        Robert Barrow
        Employees
        106
        Beta
        2.21

        Explore

        Frequently asked questions

        What is the intrinsic value of Definium Therapeutics, Inc. (DFTX)?

        InvestorsCraft does not currently publish an intrinsic value for DFTX. How the IC value is calculated.

        Is DFTX undervalued?

        InvestorsCraft does not publish an undervaluation signal for DFTX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.